Ranolazine attenuates behavioral signs of neuropathic pain

Harry J Gould III, *Louisiana State University Health Sciences Center*
Colleen J Garrett
Renee R. Donahue, *University of Kentucky*
Dennis Paul, *Louisiana State University Health Sciences Center*
Ivan Diamond, et al.

Available at: https://works.bepress.com/renee_donahue/5/
Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain. Behavioural Pharmacology 00:000–000 © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Ranolazine attenuates behavioral signs of neuropathic pain
Harry J. Gould IIIa,c,d, Colleen Garretté, Renee R. Donahuee,g, Dennis Paulb,c,d, Ivan Diamondf and Bradley K. Taylore,g

Introduction
Ranolazine (Ranexa; Gilead Sciences, Palo Alto, California, USA) was recently approved by the FDA as a cardiac, anti-ischemic, agent (Nash, 2005; Marx and Sweeney, 2006; Pham and Mehta, 2007; Sossalla et al., 2008). Ranolazine blocks skeletal muscle voltage-gated sodium channel (NaV 1.4), cardiac muscle (NaV 1.5), and neuronal (NaV 1.7, 1.8) sodium channel subtypes and produces a profound use-dependent blockade of the tetrodotoxin-sensitive, late sodium channel current associated with NaV 1.7 (Ju et al., 1996a, 1996b; Haufe et al., 2005; Belardinelli et al., 2006; Hale et al., 2008; Rajamani et al., 2008; Wang et al., 2008). Many patients spontaneously report a significant reduction in characteristic signs of neuropathic pain, including burning dysesthesia, in the lower extremities when treated with ranolazine for ischemic heart disease (C. Walker, personal communication). As recent studies link sodium channels to inflammatory pain (Gould et al., 2000, 2004) and several inherited neuropathic pain states (Nassar et al., 2004; Dib-Hajij et al., 2005; Cox et al., 2006; Fertleman et al., 2006; Waxman, 2006; Dib-Hajij et al., 2007; Drenth and Waxman, 2007; Goldberg et al., 2007), we examined whether ranolazine could reduce the mechanical and cold hyperalgesia produced in a preclinical model of acquired peripheral neuropathic pain (Decosterd and Woolf, 2000).

Methods
Subjects
All experiments were conducted in accordance with protocols that were approved and monitored by the Tulane Health Sciences Center and the University of Kentucky Institutional Animal Care and Use Committee. Male Sprague-Dawley rats, weighing 220–240 g (Harlan Sprague Dawley Inc., Indianapolis, Indiana, USA), were housed one animal per cage and maintained at 25°C and 60% humidity, on a 12 h light/dark cycle beginning at 6 a.m. and allowed free access to food and water.

Procedure
Rats were allowed to acclimate to the testing apparatus by placing them in Plexiglas boxes on a stainless steel grid for 30–60 min. Baseline determinations of responses to mechanical or cold stimuli applied to the lateral aspect of the plantar surface of the hindpaw were measured using von Frey (VF) monofilaments (Stoelting Inc., Wood Dale, Illinois, USA) or acetone, respectively (Decosterd and Woolf, 2000; Taylor et al., 2007; Intondi et al., 2008). Initially, mechanical thresholds were assessed. Hindpaws were stimulated on the lateral aspect of the plantar surface within the distribution of the sural nerve with a series of eight VF monofilaments of logarithmic stiffness. A modified version of the 50% withdrawal threshold was determined using the up–down method of Dixon, modified by Chaplan et al. (1994). First, an intermediate monofilament (number 4.31, exerts 2.0 g of force) was gently applied with enough force to bend it. This was repeated up to three times in distinct areas along the lateral paw. In case of a positive response (rapid withdrawal of the paw within 2 s), a smaller filament was tested. If no response was recorded in any of the three different areas, a larger filament was tested.

Paw withdrawal responses to cold stimuli were then measured using an acetone-loaded syringe connected to
PE-90 tubing, flared at the tip to a diameter of 3.5 mm. Surface tension maintained the delivery volume of the acetone drop to 10–12 μl. The length of time the animal lifted or shook its paw was recorded for the first 30 s. Three observations were averaged.

After the determination of preinjury responses, anesthesia was induced in rats weighing approximately 250 g with 5% isoflurane and maintained for surgical manipulation with 2–3% isoflurane. An incision was made in the skin at the level of the trifurcation of the left sciatic nerve. The overlying muscles were retracted, exposing the common peroneal, tibial, and sural nerves. With care taken to avoid mechanical stimulation of the sural branch, the common peroneal and tibial nerves were ligated with 6.0 silk (Ethicon, Somerville, New Jersey, USA), followed by transection of the intervening 1 mm segment of nerve adjacent to both the proximal and distal ligatures. The muscle was sutured with 5-0 sutures, and the skin was closed with 9 mm metal clips. Sensitivity to stimulation was reassessed 7–14 days postoperatively. Rats that showed signs of allodynia received either vehicle [intraperitoneal (i.p.) injection – propylene glycol and dichloromethane; oral gavage – distilled water titrated to pH 4.0 with dilute acetic acid and sodium hydroxide] or ranolazine (10, 30, and 100 mg/kg), administered in an experimenter-blinded, randomized design. Animals were again tested 15, 30, 60, and 90 min (i.p.) or 30, 60, 90, 120, and 180 min (orally) after drug administration. Occasionally, animals did not develop mechanical allodynia (VF threshold >5.0 g on the nerve-injured side) or exhibit cold allodynia on the day of pharmacological testing after nerve injury. In such cases (5%), testing was either terminated or the data were not included in the final analysis.

To evaluate possible ataxic effects of ranolazine administration, the ability of unoperated animals to remain on an accelerating rotarod was assessed before and after i.p. administration. Rats were placed on the rotarod, set at an initial rotating speed of 4 rpm. Immediately thereafter, speed was increased at a rate of 0.5 rpm every 5 s to a maximum of 40 rpm. Each rat was trained in this procedure three to nine times, until latency to fall was approximately 180 s. Animals that failed to remain on the rotarod for at least 100 s (two) or that remained on the rotarod for more than 300 s (one) were excluded from the study. Testing of a vehicle group (n = 4), 30 mg/kg group (n = 6), or 100 mg/kg ranolazine group (n = 5) began within 1–2 days of training. Triplicate measurements were made before and 30, 60, 90, 120, 150, and 180 min after injection. Values are represented as mean ± SEM.

**Statistical analysis**
Significance was determined with a mixed design, two-way analysis of variance with ‘drug’ as the between-subjects factor and ‘time’ as the repeated measure. If the overall F value was significant, further Bonferroni post-hoc tests were conducted to determine the effect of ‘drug’ relative to vehicle at each time point.

**Results**
Spared nerve injury increased sensitivity to mechanical and cold stimulation within the ipsilateral sural nerve distribution. As shown in Fig. 1, i.p. administration of ranolazine dose-dependently reduced both mechanical allodynia \( F(3,115) = 5.7, P < 0.005 \) and cold allodynia \( F(3,115) = 4.3, P < 0.05 \). These antialludynic effects peaked at 15–30 min and lasted for 60–90 min. Vehicle had no effect.

Only the oral route of administration of ranolazine has been approved by the FDA. Therefore, we determined whether oral ranolazine would also reduce spared nerve injury-induced allodynia. As shown in Fig. 2, oral ranolazine dose-dependently reduced both mechanical...
allodynia \[ F(3,114) = 5.1, \ P < 0.01 \] and cold allodynia \[ F(3,108) = 4.5, \ P < 0.05 \]. These effects peaked at 90 min and lasted for 90–180 min. Vehicle had no effect.

Nonselective sodium channel blockers are an integral part of the pharmacotherapy for peripheral neuropathic pain; however, severe side effects limit their use. Throughout these studies with 10–30 mg/kg ranolazine, we observed no overt signs of adverse effects. To evaluate more subtle effects on behavior, we assessed performance on an accelerating rotarod. Before drug testing, baseline latency was balanced between the three groups (vehicle, 193 ± 10 s; 30 mg/kg, 188 ± 6 s; 100 mg/kg, 189 ± 14 s). Analysis of variance did not show any effect of oral ranolazine treatment \[ F(2,60) = 0.6, \ \text{NS} \] at any time point throughout the 3-h test session \( P > 0.05 \). For example, when tested at the peak of antihyperalgesic effect (90 min, Fig. 2), rotarod latency in the vehicle, 30, and 100 mg/kg groups was 205 ± 28 s, 225 ± 17 s, and 207 ± 14 s, respectively. These data indicate that oral ranolazine did not produce ataxia.

**Discussion**

Ranolazine is approved by the FDA in the treatment of ischemic cardiac disease and angina at a dose of 500–1000 mg twice daily (approximately 2000 mg/day for a 70 kg patient). The present experiments used this dosing range in a preclinical model of neuropathic pain. We report that ranolazine reduces nerve injury-induced mechanical allodynia and cold hypersensitivity.

Systemic administration of nonselective sodium channel blockers, such as lidocaine, clearly reduce behavioral signs of neuropathic pain in humans (Backonja, 2001; Devor, 2006). Owing to ubiquitous distribution of the nine known sodium channels in many tissues of the body and the essential role of these channels in the function of excitable membranes, however, recipients risk dangerous cardiac and central nervous system effects. For example, lidocaine produces cardiac arrhythmia and ataxia at the same dosages required to yield analgesia in neuropathic pain models (Challapalli *et al.*, 2005; Gil-Gouveia and Goadsby, 2009). Potentially, these risks could be minimized by using agents that influence just a subset of sodium channel subtypes. One such agent is ranolazine, the actions of which seem restricted to NaV 1.4, 1.5, 1.7, and 1.8. In this study, ranolazine exhibited antiallodynic efficacy at doses that do not produce significant adverse effects. We suggest that ranolazine may provide a better option for treating neuropathic pain with a greater therapeutic window of efficacy than is currently available with broad-spectrum sodium channel blockers. This remains to be studied in controlled clinical trials.

Neuropathic pain is a multifaceted condition that is driven by a constellation of complex central and peripheral mechanisms. The pharmacotherapy of clinical neuropathic pain is highly variable, perhaps because of large differences in selectivity of a particular medication for a particular pain modality (Zimmerman, 2001; Erichsen *et al.*, 2003; Paul *et al.*, 2008). We speculate that the antiallodynic actions of ranolazine are mediated, at least in part, by NaV 1.7 and NaV 1.8 sodium channels located on primary sensory neurons of the peripheral nervous system. Interestingly, in this study, ranolazine exhibited antiallodynic effects at doses that do not produce significant adverse effects. We suggest that ranolazine may provide a better option for treating neuropathic pain with a greater therapeutic window of efficacy than is currently available with broad-spectrum sodium channel blockers. This remains to be studied in controlled clinical trials.
2002a, 2002b). Further investigation is warranted to determine whether ranolazine could also be an important new option in the management of the cold or mechanical allodynia that is associated with peripheral nerve injury.

Acknowledgements
H.J.G. and D.P. are supported by a grant from Gilead Sciences and by the LSU Health Sciences Center Departments of Neurology and Pharmacology. B.K.T. was supported by grants 5R29DA010356-04, 5K02DA 019656-03, and 5R01 NS045954-04.

Conflicts of interest: H.J.G. is a research consultant for Gilead Sciences. I.D. is Vice President for Neuroscience for Gilead Sciences.

References
Cephalalgia 44:954–967.
<table>
<thead>
<tr>
<th>QUERY NO.</th>
<th>Details Required</th>
<th>Author’s Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>No queries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>